Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (September 2026)
15 slides from Volitionrx's investor presentation, September 2026
Slide 1: Corporate Deck September 2026
NYSE American:VNRX Corporate Deck September 2026 Property of Volition© 2026 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Recent Achievements
Recent Achievements • Cat Paper Submitted; if published a $5 million contractual milestone payment expected • Fujifilm Vet Systems launch on automated i10 platform • Expansion into non-sepsis disease areas • Mayo Clinic Publication in Trauma. PLUS automated platform installation in Q3 2026 • KOL Pre
Slide 4: Executive Summary
Executive Summary Our mission is to save lives and improve outcomes for millions of people and animals worldwide. VolitionRx NYSE American: VNRX Medical Devices IP Powerhouse Focus Licensing IP Cancer, Sepsis Low-cost testing Commercial Worldwide Animal $23M in licensing $1.4M of Rev H1 26 Large Unm
Slide 5: Working at the Cutting Edge of Epigenetics
Working at the Cutting Edge of Epigenetics Measuring chromatin fragments Cancer NETs Global Experts in Quantifying Nucleosomes Property of Volition© 2026 Slide 5
Slide 6: Low-cost routine tests
Low-cost routine tests Platform agnostic; can be adapted to any diagnostic workflow Six 45 <10 6Hours hours 45 minutes <15 minute <10 minutes minutes <15 minutes minutes s Manual Automated Point of Care Lateral Flow Asset light - no need for own machines, labs or sales reps Property of Volition© 202
Slide 7: Commercialization Strategy
Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and out- licensing R&D • R&D conducted by Volition and its research partners • Monetize IP through licensing agreements with: • upfront payments, • milestone payments, • recurring
Slide 8: Recent Deals Signed
Recent Deals Signed • Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") for Nu.Q® NETs • Co-Marketing and Services Agreement for Nu.Q® Discover • Collaboration to optimize Nu.Q® NETs assay in diseases associated with NETosis Property of Volition©
Slide 9: Powered by Nu.Q
Powered by Nu.Q® 74 patents granted with coverage up to 20441 TAM2 Regulation Product Status Strategy Screening/ Reimbursement Sales & $4Bn Lab Developed Management Submission Licensing Multi-Cancer Proof of Sales & $23Bn CE Mark/ FDA Early Detection Concept Licensing >$3Bn First sales Sales & CE Ma
Slide 10: A world first in isolating 99% pure tumor-associated DNA from a liquid biopsy
A world first in isolating 99% pure tumor-associated DNA in cancer patient from a liquid biopsy1 • World first isolation of transcription factor-DNA from blood • World first preparation of tumor-associated DNA sequence data sets • A novel class of thousands of new biomarkers • Compelling proof of co
Slide 11: Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients • Highly correlated our established automated Nu.Q® NETs test in critically ill sepsis patients1 • Expands use-cases beyond centralized laboratory testing • Materially reduces barriers to testing patients and facilitates nucleosome measuremen
Slide 12: Projected Catalysts
Projected Catalysts Multiple licensing deals in 2025 and 2026 Catalyst 2025 2026 2027 Licensing cancer technology Reimbursement / Adoption into routine clinical practice Adoption into national program(s) Licensing Multi-Cancer Early Detection Licensing for Human NETosis / Sepsis Sales of CE marked p
Slide 13: Volition Highlights
Volition Highlights Multiple products already launched Proven Licensing model, validated in Vet Strong IP Multiple multi-billion TAM markets Low-cost, scalable platform with high margins Asset light - no need for own machines, labs, or sales reps In confidential licensing discussions with more than
Slide 14: Thank You!
Thank You! Property Strictly Confidential of Volition©| 2026 Not for Distribution | For Discussion Purposes Only Slide 14
Slide 15: Volition Nu.Q NETs. H3.1 evidence base 2020 to 2026
Volition Nu.Q® NETs. H3.1 evidence base 2020 to 2026 Basic science, models and assay above the line. Sepsis cohorts below the line. Beyond sepsis bottom row. 2023. Garcia et 2023. Cayford et 2024. Zukas et al. 2024. Atteberry et 2025. Retter, 2025.Cayford et al 2026. Cayford et al. 2025. Wargnies et